Kardigan (KARD) closed its initial public offering of 28.75 million shares, including the full exercise of the underwriters' option to purchase an additional 3.75 million.
Gross proceeds were $460 million before underwriting discounts and offering expenses with the shares sold at $16 each, the clinical-stage cardiovascular drug developer said Monday in a statement.